Key points from article :
BioAge after raising series c funding round, moved its lead therapies, BGE-117 and BGE-175, into phase 2 clinical trials.
BGE-175, will treat immune aging in older patients - initially those hospitalized with COVID-19.
“These additional funds... reverse or eradicate diseases and extend healthspan,” Kristen Fortney, CEO and co-founder, BioAge.
The new round brings the total amount of venture capital funding raised by BioAge to $127 million.
"Investors are showing more and more enthusiasm for aging as a space" - Fortney.
BioAge also announced the appointment of veteran biopharmaceutical drug developer Paul Rubin, as its chief medical officer.
Drugs are ready to begin phase 2 trials in indications that presently have no good therapeutic options.
“Our drugs can address age-related deficiencies in acute conditions, chronic diseases, resulting in healthy aging.” -Dr Rubin.
